PSMA scan to tell radiation damage from tumor growth in brain metastases
Tests a PSMA scan in people with brain metastases after radiation.
Plain-language title generated from the registry record
Registry title: Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases
Key facts
- Where
- Amsterdam, NetherlandsSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with brain metastases from lung cancer, melanoma or breast cancer, or with a brain lesion after stereotactic radiotherapy. A Ga68-PSMA PET/CT scan will be tested.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed brain metastases from non-small cell lung cancer, melanoma or breast cancer. Or a brain lesion where a metastasis was treated with stereotactic radiotherapy more than 9 months ago: either confirmed radiation necrosis, or a doubtful case between radiation necrosis and a returning metastasis. The lesion must be 10mm or larger.
- Earlier treatment
- For the radiation necrosis and doubtful groups, the earlier brain metastasis was treated with stereotactic radiotherapy (SRT) more than 9 months ago.
Main reasons for not taking part
- Known allergy to Ga68-PSMA
- Epileptic seizure less than 7 days before the scan
- Life expectancy less than 3 months
- Known prostate cancer
- Pregnancy
Read by machine on 12 November 2026.
Where in Netherlands
- Netherlands Cancer Institute-Antoni van LeeuwenhoekAmsterdam, NetherlandsContact: Lente Kroon, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The Netherlands Cancer Institute
- Trial code
- NCT07511933
- Record updated
- 24 July 2026
- Original description
This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET/CT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.Read full original descriptionShow less
Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Stereotactic Irradiated Brain Metastases: a Feasibility Study
This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET/CT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.
Inclusion: For all groups:; Written informed consent; Age ≥ 18 years old; WHO PS 0-3; Measurable lesion ≥10mm according to RANO BM; For brain metastases groups:; newly diagnosed brain metastases from either NSCLC (group 1) or melanoma (group 2) or breast cancer (group 7); For radiation necrosis groups:; Brain lesion at the location of a formerly brain metastases that has been treated with SRT (> 9 months ago), with the definite diagnosis of radiation necrosis at the location of formerly SRT-treated brain metastases of NSCLC (group 3), melanoma (group 4) and/ or breast cancer (group 8); For diagnostic dilemma groups:; Brain lesion at the location of a formerly brain metastases with a diagnostic dilemma of radiation necrosis and recurrent brain metastases of NSCLC (group 5), melanoma (group 6) and/ or breast cancer (group 9).
Exclusion: Epileptic seizure less than 7 days before Ga68-PSMA PET/CT scan; Known allergy to Ga68-PSMA; For all groups:; Life expectancy less than 3 months; Patients with known prostate carcinoma; Pregnancy.